Literature DB >> 24371759

Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib.

Tilde Kristensen1, Else Randers1, Jesper Stentoft2.   

Abstract

Previously authors have recently described an association between nilotinib therapy for chronic myeloid leukemia (CML) and severe peripheral artery disease, coronary artery disease and sudden death. We present a case report of a male patient with CML who received nilotinib therapy. He developed bilateral renal artery stenosis and renovascular hypertension. He had no history of hypertension, cardiovascular disease, or diabetes, and he was a nonsmoker. Together, these observations indicated that obtaining further understanding of the effects is necessary and that extreme caution is warranted when considering second-generation tyrosine kinase inhibitors for first-line therapy in CML.

Entities:  

Keywords:  Leukemia; Renal artery stenosis; Renovascular hypertension; Tyrosine kinase inhibitor

Year:  2012        PMID: 24371759      PMCID: PMC3787820          DOI: 10.1016/j.lrr.2012.09.002

Source DB:  PubMed          Journal:  Leuk Res Rep        ISSN: 2213-0489


  10 in total

Review 1.  New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells.

Authors:  P Valent; M Baghestanian; H C Bankl; C Sillaber; W R Sperr; J Wojta; B R Binder; K Lechner
Journal:  Thromb Haemost       Date:  2002-05       Impact factor: 5.249

2.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

3.  Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.

Authors:  Ayalew Tefferi; Louis Letendre
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

4.  Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis.

Authors:  Christopher Franco; Karen Britto; Eric Wong; Guangpei Hou; Su-Ning Zhu; Mian Chen; Myron I Cybulsky; Michelle P Bendeck
Journal:  Circ Res       Date:  2009-10-15       Impact factor: 17.367

Review 5.  Current approaches to renovascular hypertension.

Authors:  Stephen C Textor
Journal:  Med Clin North Am       Date:  2009-05       Impact factor: 5.456

Review 6.  Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.

Authors:  Anat Gafter-Gvili; Ron Ram; Uzi Gafter; Ofer Shpilberg; Pia Raanani
Journal:  Leuk Res       Date:  2009-07-28       Impact factor: 3.156

Review 7.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Authors:  Jörg Thomas Hartmann; Michael Haap; Hans-Georg Kopp; Hans-Peter Lipp
Journal:  Curr Drug Metab       Date:  2009-06       Impact factor: 3.731

8.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

9.  Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.

Authors:  Sarah A Holstein; John B Stokes; Raymond J Hohl
Journal:  Leuk Res       Date:  2008-10-02       Impact factor: 3.156

10.  Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

Authors:  M Breccia; M Muscaritoli; F Gentilini; R Latagliata; I Carmosino; F Rossi Fanelli; G Alimena
Journal:  Leuk Res       Date:  2007-03-26       Impact factor: 3.156

  10 in total
  4 in total

Review 1.  An update on cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman
Journal:  Trends Cardiovasc Med       Date:  2014-07-22       Impact factor: 6.677

Review 2.  Vascular Complications of Cancer Chemotherapy.

Authors:  Alan C Cameron; Rhian M Touyz; Ninian N Lang
Journal:  Can J Cardiol       Date:  2015-12-28       Impact factor: 5.223

3.  Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.

Authors:  Syed O Amin; Marcel Ruzicka; Kevin D Burns; Isabelle A Bence-Bruckler; Stephen E Ryan; Adnan Hadziomerovic; Swapnil Hiremath
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-03-16       Impact factor: 3.738

4.  SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions.

Authors:  Lei L Chen; Jing Zhu; Jonathan Schumacher; Chongjuan Wei; Latha Ramdas; Victor G Prieto; Arnie Jimenez; Marco A Velasco; Sheryl R Tripp; Robert H I Andtbacka; Launce Gouw; George M Rodgers; Liansheng Zhang; Benjamin K Chan; Pamela B Cassidy; Robert S Benjamin; Sancy A Leachman; Marsha L Frazier
Journal:  PLoS One       Date:  2017-09-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.